• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Insurers Don't Want to Pay for Biogen (BIIB) $56,000 Alzheimer’s Drug Aduhelm - Bloomberg

Quote




STAT: Insurers want proof before paying for Aduhelm

Health insurance companies are reticent to pay for Biogen drug Aduhelm, saying they want more proof that it is actually effective in slowing the rate that Alzheimer’s patients decline. One insurer told Bloomberg that Aduhelm isn’t medically necessary for the neurodegenerative disease “as a clinical benefit has not been established.” This is stalling sales of the $56,000-a-year drug even more than before. However, Humana will cover the drug for patients who resemble those who benefited from the drug in trials.

It’s currently very difficult to get approved for the Biogen drug: Despite hours of attempting to get the greenlight from insurers, doctors can very rarely help their patients get insurance coverage for Aduhelm. Some patients are paying out of pocket, or seeking out free supplies — but the vast majority are simply not getting access to the controversial drug.
 
















Top Bottom
Back
Quote